[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diastolic-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diastolic-heart-failure":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,57,83,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100444229","assessment-of-ccm-in-hf-with-higher-ejection-fraction-100444229",false,"NCT05064709","Assessment of CCM in HF With Higher Ejection Fraction","Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction","AIM HIGHer","Inclusion Criteria:\n\n1. Signed and dated informed consent form;\n2. Male or non-pregnant female, 18 years or older;\n3. Diagnosed with symptomatic heart failure;\n4. LVEF ≥40 and ≤70% (as assessed by site echo);\n5. A. Heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent OR B. If there is no heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent, an elevated BMI-adjusted natriuretic peptide value must be achieved (Refer to Table 1 in Section 9.2.6)\n6. Subjects must meet one of the following conditions:\n\n   * Have stable, scheduled oral loop diuretic treatment (not just PRN) for a minimum of 30 days before providing study consent unless there is a documented allergy or intolerance.\n   * Eligibility for enrollment is maintained for patients on an SGLT2 inhibitor without prescribed concurrent standing loop diuretic therapy if investigators provide instructions for a flexible PRN diuretic regimen (deemed appropriate by the clinician in response to symptoms or weight gain) Note: Stable is defined as no more than a 100% increase or 50% decrease in dose within the last 30 days. A one-time hold of diuretic dosing for 24 hours during the 30-day period is allowed and not an exclusionary event.\n\nExclusion Criteria:\n\n1. Resting ventricular rate \\\u003C50 or \\>110 bpm;\n2. Resting systolic blood pressure \\\u003C100 or ≥160 mmHg;\n3. BMI greater than 46\n4. Any severe valvular stenotic disease or any severe valvular regurgitation;\n5. Mechanical tricuspid valve;\n6. Complex congenital heart disease;\n7. Exercise tolerance limited by a condition other than heart failure that, in the opinion of the investigator, contributes significantly to the primary symptoms of shortness of breath and\u002For exercise intolerance;\n8. Unable to walk at least 100 meters or walks more than 450 meters during a 6MWT;\n9. A KCCQ CCS score higher than 85;\n10. Hypertrophic, infiltrative\u002Frestrictive or inflammatory cardiomyopathy;\n11. Unstable angina pectoris within 30 days prior to study consent;\n12. Acute, decompensated heart failure requiring IV therapy or ultrafiltration within 30 days prior to consent, in the hospital or an outpatient setting;\n13. Receiving cardiac resynchronization therapy (CRT); NOTE: Subjects with active\u002Fongoing cardiac resynchronization therapy (CRT) implanted more than one year ago are eligible for inclusion if they are currently classified as NYHA class III or higher.\n14. Scheduled for a cardiac surgery or a percutaneous cardiac intervention (PCI) or have undergone cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;\n15. Myocardial infarction within 90 days prior to study consent;\n16. Prior heart transplant or ventricular assist device;\n17. Planning to become pregnant during the study;\n18. Dialysis (permanent) or GFR \\\u003C15 ml\u002Fmin\u002F1.73m2;\n19. Participating in another investigational drug or device study that may interfere with the interpretation of study data;\n20. Currently undergoing active chemotherapeutic and\u002For radiation treatment for cancer or has a history of chemotherapy during the 2-year period prior to study consent;\n21. Expected lifespan of less than 18 months from time of study consent;\n22. Unable to follow through study protocol for any reasons in the investigator's judgement.","ALL","18 Years",{"count":20,"type":21},1500,"ESTIMATED","INTERVENTIONAL",[24],"NA","The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.",[27,28,29,30,31],"Heart Failure","Heart Failure With Preserved Ejection Fraction","Heart Failure With Mid Range Ejection Fraction","Heart Failure With Moderately Reduced Ejection Fraction","Diastolic Heart Failure",[33,34,35,36,37,38,39,40,41,42,43],"HFpEF","Heart failure","CCM","CCM therapy","cardiac contractility modulation","symptomatic heart failure","left ventricular ejection fraction","LVEF","Optimizer","Optimizer Smart Mini","Quality of Life","RECRUITING","2026-06-24",{"date":47,"type":48},"2026-06-26","ACTUAL",{"date":50,"type":48},"2022-02-03",{"date":52,"type":21},"2029-02-01",{"name":54,"class":55},"Impulse Dynamics","INDUSTRY",105,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":66,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100643802","heart-failure-and-postoperative-outcome-in-surgery---a-national-registry-study-100643802","NCT07634822","Heart Failure and Postoperative Outcome in Surgery - a National Registry Study","Incidence of Heart Failure and Its Association With Postoperative Mortality in Surgery - a National Registry Study","Inclusion Criteria:\n\n* ≥18 years of age who underwent surgery in Sweden between 1 Jan 2021-31 Dec 2024 and SPOR registered operation.\n\nExclusion Criteria:\n\n* ASA 6 (deceased patient, organ donation).\n* Cardiac surgery",{"count":65,"type":21},2200000,"1 Year","OBSERVATIONAL","The study is an exploratory study that aims to explore the incidence of heart failure in a national surgical cohort, and to compare postoperative mortality and morbidity in patients with and without heart failure. Furthermore, we want to investigate differences in the incidence of heart failure and its impact on postoperative morbidity and mortality in day surgery compared to inpatient surgery.",[27,31,70],"Systolic Heart Failure","NOT_YET_RECRUITING","2026-06-02",{"date":74,"type":48},"2026-06-09",{"date":76,"type":21},"2026-08",{"date":78,"type":21},"2030-12",{"name":80,"class":81},"Umeå University","OTHER",2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100517302","purinergic-signaling-and-the-postmenopausal-heart-100517302","NCT06015776","Purinergic Signaling and the Postmenopausal Heart","PGC-1, Purines and the Postmenopausal Heart","Inclusion Criteria:\n\n* Patients undergoing cardiac surgery under cardiopulmonary bypass.\n\nExclusion Criteria:\n\n* Refusal to participate\n* Emergency surgery\n* Pre-existing heart block\n* Preexisting atrial fibrillation\n* Redo surgery\n* Estrogen or hormone replacement therapy\n* History of chronic heart failure\n* History of major kidney disease","30 Years","88 Years",{"count":93,"type":21},500,"There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.",[31,28],"2026-03-18",{"date":98,"type":48},"2026-03-20",{"date":100,"type":48},"2019-07-01",{"date":102,"type":21},"2030-06",{"name":104,"class":81},"Beth Israel Deaconess Medical Center",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":82},"100577973","left-ventricular-reverse-remodeling-evaluation-after-surgical-correction-of-aortic-regurgitation-100577973","NCT06805253","Left Ventricular Reverse Remodeling Evaluation After Surgical Correction of Aortic Regurgitation","Left Ventricular Reverse Remodeling Outcomes Evaluation in Patients With Aortic Regurgitation After Surgical Treatment","ORMIX","Inclusion Criteria:\n\n* Age over 18 years\n* Planned primary elective surgery for chronic aortic regurgitation\n* Presence of functional mitral regurgitation\n* End-diastolic volume of the left ventricle \\>= 250 ml\n\nExclusion Criteria:\n\n* Infectious endocarditis\n* History of myocardial infarction\n* Indications on simultaneous myocardial revascularisation\n* Acute aortic regurgitation of any etiology\n* Previously diagnosed dilatation of the left ventricle, not associated with the development of aortic regurgitation\n* Long-term persistent or permanent form of atrial fibrillation\n* Pregnancy in the first 12 months after surgery\n* Simultaneous participation in other studies\n* Presence of implanted pacemakers\n* Refusal to sign informed consent\n* Acute coronary event diagnosed within 12 months after aortic valve surgery\n* Indications for resynchronization therapy or permanent right ventricular pacing in the first 12 months after aortic valve surgery\n* Re-do cardiac surgery for any reason within 12 months after aortic valve surgery",{"count":115,"type":21},120,"Investigators assume that surgical correction approach to functional mitral regurgitation during intervention for chronic aortic regurgitation in patients with severe enlargement of the left heart chambers influences reverse remodeling of the left ventricle (LV) in the postoperative period. It is suggested that functional mitral regurgitation (MR) provides supra-physiological left ventricle volume overload and this fact plays positive role in early-stage post-operative left ventricle volume and function recovery. LV volume, systolic and diastolic function will be monitored with echocardiography (EchoCG) along with life quality in patients with different grades of functional mitral regurgitation secondary to severe chronic aortic insufficiency after surgical treatment of aortic regurgitation.",[118,119,120,121,122,31],"Aortic Valve Regurgitation","Mitral Valve Regurgitation","Left Ventricle Dilated","Left Atrium Dilated","Systolic Left Ventricular Heart Failure",[124,125,126,127],"reverse remodeling","left ventricle dilatation","mitral valve functional regurgitation recovery","left ventricle reverse remodeling","2025-06-05",{"date":130,"type":48},"2025-06-11",{"date":132,"type":48},"2024-05-09",{"date":134,"type":21},"2030-05",{"name":136,"class":81},"Petrovsky National Research Centre of Surgery"]